Daousi C, Foy P M, MacFarlane I A
Diabetes and Endocrinology Research Group, University Hospital Aintree, Clinical Sciences Centre, 3rd Floor, Lower Lane, Liverpool L9 7AL, UK.
J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):93-5. doi: 10.1136/jnnp.2006.095661.
Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive. It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid and aggressive tumour expansion.
To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.
Patients studied were: (1) a female patient with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma. Changes in tumour size on serial magnetic resonance imaging scans, and restoration of euthyroidism were studied.
No marked changes in tumour size or features of aggressiveness occurred in these patients over periods of 8 and 12 years. Euthyroidism was restored and maintained in both patients.
Ablative thyroid treatment can be a safe and successful option to treat TSHomas, but long-term and close follow-up of these patients is mandatory to ensure that the size and behaviour of the tumours do not change markedly.
促甲状腺激素(TSH)分泌型垂体腺瘤(TSH瘤)是一种罕见的、具有侵袭性的肿瘤。有人认为,患有此类肿瘤的患者不应考虑进行甲状腺手术或放射性碘治疗,因为这些治疗可能会促使肿瘤迅速且侵袭性地生长。
研究甲状腺消融治疗对两名TSH瘤患者肿瘤大小和甲状腺状态的影响,这两名患者在开始治疗前腺瘤大小已得到明确记录。
研究的患者为:(1)一名患有TSH瘤的女性患者,她拒绝接受垂体手术,而是接受了全甲状腺切除术;(2)一名男性患者,他选择对复发性TSH瘤进行放射性碘治疗。研究了系列磁共振成像扫描中肿瘤大小的变化以及甲状腺功能正常的恢复情况。
在8年和12年的时间里,这些患者的肿瘤大小或侵袭性特征均未发生明显变化。两名患者均恢复并维持了甲状腺功能正常。
甲状腺消融治疗可以是治疗TSH瘤的一种安全且成功的选择,但必须对这些患者进行长期密切随访,以确保肿瘤的大小和行为不会发生明显变化。